<table>
<thead>
<tr>
<th>Guideline Page and Request</th>
<th>Panel Discussion/References</th>
<th>Institution Vote</th>
</tr>
</thead>
</table>
| **BRCA-1**    
External request  
Submission request from Myriad Genetic Laboratories to  
1. Replace “BRCA1/2 testing criteria” with “Hereditary Breast and Ovarian cancer genes (which besides BRCA1/2 may include Lynch syndrome genes, CDH1, STK11, BRIP1, PALB2, RAD51C, RAD51D, CHEK2 and ATM).”  
2. Add the following footnote to the new testing criteria, “Due to the link between breast cancer and multiple genes implicated in hereditary cancer syndromes, testing for a multigene panel should be strongly considered as an alternative to BRCA1/2 testing alone.”  
   - For the BRCA-1 page, the panel consensus was to not replace “BRCA1/2 testing criteria” with “Hereditary Breast and Ovarian cancer genes (which besides BRCA1/2 may include Lynch syndrome genes, CDH1, STK11, BRIP1, PALB2, RAD51C, RAD51D, CHEK2 and ATM)” or to add the suggested footnote due to differences with the noted genes such as phenotype, age of onset, risk estimates, and management recommendations.  
   - See Submission for references. | YES 17 0 10 |

| **External request**  
Submission request from Myriad Genetic Laboratories to  
1. Expand the BRCA1/2 testing criteria to include all patients with a personal diagnosis of pancreatic cancer.  
2. Add the following footnote to the new “Personal history of pancreatic cancer” testing criteria, “Due to the link between pancreatic cancer and multiple genes implicated in hereditary cancer syndromes, testing for a multigene panel should be strongly considered as an alternative to BRCA1/2 testing alone.”  
   - Based on the submitted references and panel discussion, the consensus was to not expand the BRCA1/2 testing criteria to include all patients with a personal diagnosis of pancreatic cancer or add the suggested footnote due to differences with the noted genes such as phenotype, age of onset, risk estimates, and management recommendations.  
   - See Submission for references. | YES 17 0 10 |
cancer and multiple additional genes (i.e., *ATM, PALB2, CDKN2A, MLH1, MSH2*) implicated in hereditary cancer syndromes, testing with a multigene panel should be strongly considered as an alternative to *BRCA1/2* testing alone."